|
|
9221 Corbin Ave Suite 200
Northridge, CA 91324 United States
phone:1-818-356-9400
fax:1-818-356-9416
|
|
| Symbol |
AVH.AX |
| Exchange |
ASX |
| Founded |
2008 |
| Employees |
21 |
|
|
| www.avitamedical.com/
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Technology that uses patients' own skin to treat skin defects |
|
| Management |
| William Dolphin, CEO; Tiziano Caldera, General Manager; Lorraine Glover, General Manager;
William Marshall, VP Operations;
Andrew Quick, VP Research and Technology
Eric Airiau - Sales Manager, EMEA |
| |
|
|
|
|
|
|
|
| Keywords |
| Tissue, cell replacement, regenerative medicine |
|
|
|
| Description |
|
Avita Medical produces ReCell®Spray-On Skin™, an autologous cell harvesting, processing, and delivery technology that enables surgeons and clinicians to treat skin defects using the patient's own cells in a regenerative process that accelerates healing, minimizes scar formation, eliminates tissue rejection, and reintroduces proper texture and pigmentation to the skin. ReCell® produces a suspension of skin cells from a sample taken from skin surrounding the area to be treated. Once sprayed onto the affected area, the patient's healthy cells enter into a phase of rapid growth, proliferation, and migration, thereby reconstructing a new skin that matches the surrounding tissue. ReCell® has been designed for use in a variety of wound, plastic, reconstructive, burn, and cosmetic procedures. This later-stage biotechnology company's procedure is performed on-site, utilizes a patented and proprietary spray-on application, takes approximately 30 minutes to complete, and does not require laboratory facilities. |
|
| Products / Services |
ReCell Spray-On Skin is a stand-alone, rapid, autologous cell harvesting, processing and delivery
technology that enables surgeons and clinicians to treat skin defects using the patient's own cells in a
regenerative process, accelerating healing, minimizing scar formation, eliminating tissue rejection and
reintroducing pigmentation to the skin. ReCell has been designed for use in a wide variety of wound, plastic, reconstructive, burn and cosmetic procedures. The procedure is performed on site, utilizes a patented and proprietary 'spray-on' application technique, takes approximately 30 minutes to complete, and does not require laboratory facilities.
|
|
| Technology / Differentiation |
| Developed as an "off-the-shelf" kit, ReCell enables a thin split thickness biopsy, taken at the time of
the procedure, to be processed into an immediate cell population for delivery onto the surface of the
treatment area using a highly efficient, easy-to-use proprietary 'spray-on' application process. Tissue
collection, cell segregation, and preparation of the cell suspension takes approximately 20-30 minutes in
total during which time the treatment area is prepared. Once processed, the cell suspension is available
for immediate use and can cover a treatment area up to 80 times the area of the donor biopsy. ReCell enables the delivery of keratinocytes, melanocytes, fibroblasts and Langerhans cells harvested from the epidermal-dermal junction for application onto a wound surface in order to promote rapid and effective healing. ReCell has been clinically demonstrated to accelerate healing, minimize scar formation, eliminate tissue rejection and reintroduce pigmentation into hypopigmented areas. |
|
| Market / Customers |
Overall stem cell product sales in the United States totaled $36 million in 2007 and are expected to reach $87 million - a 144 percent increase - in 2008. Nearly three million patients worldwide will be treated with stem cell products by 2015.
|
|
| Status |
| ReCell is on market and generating revenues. ReCell is cleared for sales in Europe (CE Mark), Australia (TGA), China (SFDA) and the Middle East. ReCell is currently in Phase III trials with the FDA for clearance to market in the US. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members